findmyKOL
Clinical trialNCT03732820Active, not recruitingPhase 3Interventional

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

SponsorAstraZenecaEnrollment895Metastatic Castration-resistant Prostate Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

132 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Research Site

    Box Hill, Australia

  • Research Site

    Darlinghurst, Australia

  • Research Site

    Greenslopes, Australia

  • Research Site

    Herston, Australia

  • Research Site

    Kingswood, Australia

  • Research Site

    Kurralta Park, Australia

  • Research Site

    St Albans, Australia

  • Research Site

    Waratah, Australia

Belgium
  • Research Site

    Ghent, Belgium

Brazil
  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Curitiba, Brazil

  • Research Site

    Fortaleza, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    São José do Rio Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

Canada
  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Kelowna, British Columbia, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    London, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Greenfield Park, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

Chile
  • Research Site

    Santiago, Chile

  • Research Site

    Santiago, Chile

  • Research Site

    Temuco, Chile

  • Research Site

    Viña del Mar, Chile

Czechia
  • Research Site

    Brno, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Prague, Czechia

France
  • Research Site

    Angers, France

  • Research Site

    Besançon, France

  • Research Site

    Caen, France

  • Research Site

    Pierre-Bénite, France

  • Research Site

    Quimper, France

92 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Oct 2018
Primary completion
30 Jul 2021
Completion
5 Feb 2027
Last update posted
2 Jun 2026
Registered enrollment
895
Registry id
NCT03732820

Cross-registrations

EU-CTR / CTIS (EudraCT)2018-002011-10

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.